{"title":"绝经后妇女二氧化碳阴道激光治疗后阴道乳杆菌的改变和阴道症状的缓解。","authors":"Teerapan Seehanantawong, Pisut Pongchaikul, Rujira Wattanayingcharoenchai, Komkrit Aimjirakul, Orawee Chinthakanan, Pitak Santanirand, Jittima Manonai","doi":"10.2147/IJWH.S537531","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To assess changes in the prevalence and abundance of vaginal Lactobacillus after fractional micro-ablative carbon dioxide (CO<sub>2</sub>) therapy in postmenopausal women with vulvovaginal atrophy (VVA).</p><p><strong>Methods: </strong>This prospective, single-arm clinical study was conducted in postmenopausal women who underwent treatment with CO<sub>2</sub> laser therapy. Eligible participants were enrolled before the first session of therapy and evaluated at weeks 0, 8, 20, and 32. Vaginal fluid samples were collected using a standardized protocol and processed for Gram staining and expanded quantitative urine culture (EQUC). The level of Lactobacillus was assessed using the Nugent scoring system. The secondary outcomes included the prevalence of Lactobacillus, VVA symptoms, and vaginal pH. The results were analyzed using multilevel mixed-effects linear regression and paired <i>t</i>-tests.</p><p><strong>Results: </strong>Forty-three postmenopausal women with at least one symptom of VVA, with a mean age of 67.3 ± 8.7 years, were recruited. The mean Nugent scores for Lactobacillus morphotypes gradually decreased from 2.84 (95% CI: 2.38-3.29) at baseline to 2.28 (95% CI: 1.79-2.77) at week 8, 2.09 (95% CI: 1.60-2.58) at week 20, and further to 1.84 (95% CI: 1.31-2.35) at week 32 (p < 0.05). The prevalence of Lactobacillus increased from 27.9% (12/43) at baseline to 48.8% (21/43) at week 8, 55.8% (24/43) at week 20, and 58.1% (25/43) at week 32 (p < 0.05). VVA symptom severity and vaginal pH consistently declined from baseline to week 32 (p < 0.05).</p><p><strong>Conclusion: </strong>Fractional CO<sub>2</sub> laser treatment improved the prevalence and level of Lactobacillus after treatment and sustained improvements were observed at 3- and 6-month follow-ups. These positive effects were correlated with improvements in VVA symptoms.</p>","PeriodicalId":14356,"journal":{"name":"International Journal of Women's Health","volume":"17 ","pages":"3133-3144"},"PeriodicalIF":2.6000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12466563/pdf/","citationCount":"0","resultStr":"{\"title\":\"Vaginal Lactobacillus Alteration and Vaginal Symptom Relief After Carbon Dioxide Vaginal Laser Therapy in Postmenopausal Women.\",\"authors\":\"Teerapan Seehanantawong, Pisut Pongchaikul, Rujira Wattanayingcharoenchai, Komkrit Aimjirakul, Orawee Chinthakanan, Pitak Santanirand, Jittima Manonai\",\"doi\":\"10.2147/IJWH.S537531\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To assess changes in the prevalence and abundance of vaginal Lactobacillus after fractional micro-ablative carbon dioxide (CO<sub>2</sub>) therapy in postmenopausal women with vulvovaginal atrophy (VVA).</p><p><strong>Methods: </strong>This prospective, single-arm clinical study was conducted in postmenopausal women who underwent treatment with CO<sub>2</sub> laser therapy. Eligible participants were enrolled before the first session of therapy and evaluated at weeks 0, 8, 20, and 32. Vaginal fluid samples were collected using a standardized protocol and processed for Gram staining and expanded quantitative urine culture (EQUC). The level of Lactobacillus was assessed using the Nugent scoring system. The secondary outcomes included the prevalence of Lactobacillus, VVA symptoms, and vaginal pH. The results were analyzed using multilevel mixed-effects linear regression and paired <i>t</i>-tests.</p><p><strong>Results: </strong>Forty-three postmenopausal women with at least one symptom of VVA, with a mean age of 67.3 ± 8.7 years, were recruited. The mean Nugent scores for Lactobacillus morphotypes gradually decreased from 2.84 (95% CI: 2.38-3.29) at baseline to 2.28 (95% CI: 1.79-2.77) at week 8, 2.09 (95% CI: 1.60-2.58) at week 20, and further to 1.84 (95% CI: 1.31-2.35) at week 32 (p < 0.05). The prevalence of Lactobacillus increased from 27.9% (12/43) at baseline to 48.8% (21/43) at week 8, 55.8% (24/43) at week 20, and 58.1% (25/43) at week 32 (p < 0.05). VVA symptom severity and vaginal pH consistently declined from baseline to week 32 (p < 0.05).</p><p><strong>Conclusion: </strong>Fractional CO<sub>2</sub> laser treatment improved the prevalence and level of Lactobacillus after treatment and sustained improvements were observed at 3- and 6-month follow-ups. These positive effects were correlated with improvements in VVA symptoms.</p>\",\"PeriodicalId\":14356,\"journal\":{\"name\":\"International Journal of Women's Health\",\"volume\":\"17 \",\"pages\":\"3133-3144\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-09-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12466563/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Women's Health\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/IJWH.S537531\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Women's Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IJWH.S537531","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
Vaginal Lactobacillus Alteration and Vaginal Symptom Relief After Carbon Dioxide Vaginal Laser Therapy in Postmenopausal Women.
Objective: To assess changes in the prevalence and abundance of vaginal Lactobacillus after fractional micro-ablative carbon dioxide (CO2) therapy in postmenopausal women with vulvovaginal atrophy (VVA).
Methods: This prospective, single-arm clinical study was conducted in postmenopausal women who underwent treatment with CO2 laser therapy. Eligible participants were enrolled before the first session of therapy and evaluated at weeks 0, 8, 20, and 32. Vaginal fluid samples were collected using a standardized protocol and processed for Gram staining and expanded quantitative urine culture (EQUC). The level of Lactobacillus was assessed using the Nugent scoring system. The secondary outcomes included the prevalence of Lactobacillus, VVA symptoms, and vaginal pH. The results were analyzed using multilevel mixed-effects linear regression and paired t-tests.
Results: Forty-three postmenopausal women with at least one symptom of VVA, with a mean age of 67.3 ± 8.7 years, were recruited. The mean Nugent scores for Lactobacillus morphotypes gradually decreased from 2.84 (95% CI: 2.38-3.29) at baseline to 2.28 (95% CI: 1.79-2.77) at week 8, 2.09 (95% CI: 1.60-2.58) at week 20, and further to 1.84 (95% CI: 1.31-2.35) at week 32 (p < 0.05). The prevalence of Lactobacillus increased from 27.9% (12/43) at baseline to 48.8% (21/43) at week 8, 55.8% (24/43) at week 20, and 58.1% (25/43) at week 32 (p < 0.05). VVA symptom severity and vaginal pH consistently declined from baseline to week 32 (p < 0.05).
Conclusion: Fractional CO2 laser treatment improved the prevalence and level of Lactobacillus after treatment and sustained improvements were observed at 3- and 6-month follow-ups. These positive effects were correlated with improvements in VVA symptoms.
期刊介绍:
International Journal of Women''s Health is an international, peer-reviewed, open access, online journal. Publishing original research, reports, editorials, reviews and commentaries on all aspects of women''s healthcare including gynecology, obstetrics, and breast cancer. Subject areas include: Chronic conditions including cancers of various organs specific and not specific to women Migraine, headaches, arthritis, osteoporosis Endocrine and autoimmune syndromes - asthma, multiple sclerosis, lupus, diabetes Sexual and reproductive health including fertility patterns and emerging technologies to address infertility Infectious disease with chronic sequelae including HIV/AIDS, HPV, PID, and other STDs Psychological and psychosocial conditions - depression across the life span, substance abuse, domestic violence Health maintenance among aging females - factors affecting the quality of life including physical, social and mental issues Avenues for health promotion and disease prevention across the life span Male vs female incidence comparisons for conditions that affect both genders.